Zoetis (NYSE:ZTS) was downgraded by Hilliard Lyons to a “neutral” rating in a note issued to investors on Thursday, The Fly reports. The analysts noted that the move was a valuation call.
ZTS has been the topic of several other reports. Zacks Investment Research downgraded Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price on the stock. in a report on Saturday, January 13th. BMO Capital Markets reiterated a “hold” rating on shares of Zoetis in a report on Monday, January 8th. Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Thursday, January 4th. Cowen set a $85.00 target price on Zoetis and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, Craig Hallum reiterated a “buy” rating and set a $85.00 target price (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $81.61.
NYSE ZTS opened at $85.52 on Thursday. The stock has a market capitalization of $41,571.68, a PE ratio of 35.82, a PEG ratio of 1.90 and a beta of 0.96. Zoetis has a 1-year low of $53.65 and a 1-year high of $86.38. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.66 by $0.03. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The company’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $0.47 EPS. sell-side analysts expect that Zoetis will post 3.04 EPS for the current fiscal year.
In other news, EVP Roxanne Lagano sold 35,663 shares of Zoetis stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the transaction, the executive vice president now owns 49,919 shares in the company, valued at approximately $4,044,437.38. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Heidi C. Chen sold 37,453 shares of Zoetis stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 112,952 shares of company stock valued at $9,219,843. Insiders own 0.35% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of ZTS. Robecosam AG boosted its position in Zoetis by 4.6% during the 4th quarter. Robecosam AG now owns 15,346 shares of the company’s stock valued at $1,111,000 after purchasing an additional 679 shares during the period. Daiwa Securities Group Inc. boosted its position in Zoetis by 4.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 16,828 shares of the company’s stock valued at $1,212,000 after purchasing an additional 697 shares during the period. Sandy Spring Bank boosted its position in Zoetis by 2.3% during the 4th quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock valued at $2,235,000 after purchasing an additional 708 shares during the period. Penserra Capital Management LLC boosted its position in Zoetis by 18.6% during the 4th quarter. Penserra Capital Management LLC now owns 4,550 shares of the company’s stock valued at $327,000 after purchasing an additional 715 shares during the period. Finally, Advisory Services Network LLC boosted its position in Zoetis by 42.4% during the 4th quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock valued at $175,000 after purchasing an additional 721 shares during the period. Institutional investors own 92.33% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zoetis (ZTS) Lowered to “Neutral” at Hilliard Lyons” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/19/zoetis-zts-lowered-to-neutral-at-hilliard-lyons.html.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.